Fri 21 Feb 2025 - Historically, mortality improvements have occurred in waves, such as the rapid reduction in cardiovascular disease (CVD) mortality in the second half of the 20th century and early 21st century. This reduction in CVD deaths has in part rendered the contribution of cancer to future mortality improvement and longevity risk even more material.
The aim of this workshop is to:
We may be on the cusp of another significant shift, propelled by breakthroughs in cancer therapies. To gain a good grasp of this potential new regimen, a review of cancer risk factors and site-specific mortality trends will provide a window into the future of cancer mortality risks.
This risk will then be weighed against recent treatment advances, particularly chimeric antigen receptor-T cell therapy (CAR-T), immune checkpoint inhibitors (ICI) and mRNA vaccines, and their potential to reshape actuarial assumptions about mortality. Given the demographic profile of cancer mortality, these advances are likely to translate into differential improvements by sex and key age groups.
We aim to provide actuaries with a comprehensive understanding of the past, present and future of cancer mortality and which demographic groups are likely to benefit. This knowledge will enhance their ability to assess longevity risk and refine mortality forecasting models. The workshop is designed for actuaries across all experience levels who are interested in incorporating medical perspectives into life product assessments, including pensions and annuities.
| Members | Book for free |
| Non-members | £45 |